US FDA asks advisory panel to examine dental amalgam safety
This article was originally published in RAJ Devices
The US Food and Drug Administration is asking its external experts to examine several scientific issues that may affect the regulation of dental amalgam, used for direct filling of carious lesions or structural defects in teeth1.
You may also be interested in...
Citing challenges posed by the COVID-19 pandemic, EU regulators have extended the deadline for companies to finish nitrosamine-related risk evaluations.
The Australian health care products regulator is inviting feedback on proposed measures to clarify the boundary for software-based products that are captured under the regulatory framework for medical devices.
A draft EU guideline explains how companies can ensure that data from ongoing clinical trials remains relevant for regulatory decision-making despite problems posed by the COVID-19 pandemic.